Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
fibrosis10255 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A06573 | 32822325 | Orv Hetil | The potential role of organic and conventional yoghurt consumption in the treatment of non-alcoholic fatty liver disease | 2020 | Details |
| A06576 | 32822095 | J Magn Reson Imaging | Multiparametric MRI in Patients With Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A06592 | 32815965 | Food Funct | A multi-targeting strategy to ameliorate high-fat-diet- and fructose-induced (western diet-induced) non-alcoholic fatty liver disease (NAFLD) with supplementation of a mixture of legume ethanol extracts. | 2020 | Details |
| A06594 | 32814993 | Curr Gastroenterol Rep | Emerging New Diagnostic Modalities and Therapies of Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A06596 | 32813194 | Hepatol Int | Benefits of prolonged-release pirfenidone plus standard of care treatment in patients with advanced liver fibrosis: PROMETEO study. | 2020 | Details |
| A06604 | 32810900 | Liver Int | Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease. | 2020 | Details |
| A06615 | 32807638 | Nutr Metab Cardiovasc Dis | Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic fatty liver disease. | 2020 | Details |
| A06618 | 32805401 | Free Radic Biol Med | Cyanidin-3-O-β-glucoside inactivates NLRP3 inflammasome and alleviates alcoholic steatohepatitis via SirT1/NF-κB signaling pathway. | 2020 | Details |
| A06619 | 32805210 | Chem Biol Interact | High fat diet-triggered non-alcoholic fatty liver disease: A review of proposed mechanisms. | 2020 | Details |
| A06624 | 32803141 | Cardiovasc Endocrinol Metab | Nonalcoholic fatty liver disease: implications for endocrinologists and cardiologists. | 2020 | Details |
| A06626 | 32802809 | J Hepatocell Carcinoma | Resection of NAFLD-Associated HCC: Patient Selection and Reported Outcomes. | 2020 | Details |
| A06627 | 32801462 | J Clin Biochem Nutr | Epigallocatechin-3-gallate (EGCG) attenuates non-alcoholic fatty liver disease via modulating the interaction between gut microbiota and bile acids. | 2020 | Details |
| A06628 | 32801031 | J Nutr Biochem | Anti-inflammatory activities of green tea catechins along the gut-liver axis in nonalcoholic fatty liver disease: lessons learned from preclinical and human studies. | 2020 | Details |
| A06630 | 32801011 | Clin Gastroenterol Hepatol | Prevalence of Fatty Liver Disease and Fibrosis Detected by Transient Elastography in Adults in the United States, 2017-2018. | 2020 | Details |
| A06636 | 32799384 | Liver Int | Unhealthy lifestyle habits and physical inactivity among Asian patients with non-alcoholic fatty liver disease. | 2020 | Details |
| A06640 | 32798017 | Biochem Biophys Res Commun | GPR91 antagonist and TGF-β inhibitor suppressed collagen production of high glucose and succinate induced HSC activation. | 2020 | Details |
| A06644 | 32796353 | Eur J Gastroenterol Hepatol | A personalized treatment program in persons with type 2 diabetes is associated with a reduction in liver steatosis. | 2021 | Details |
| A06651 | 32794259 | Hepatology | The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in NASH. | 2020 | Details |
| A06652 | 32793612 | Front Med (Lausanne) | FIB-4 Regression With Direct-Acting Antiviral Therapy in Patients With Hepatitis C Infection: A Safety-Net Hospital Experience. | 2020 | Details |
| A06657 | 32791791 | Zhonghua Gan Zang Bing Za Zhi | [Diagnostic value of liver stiffness measurement for the evaluation of liver fibrosis in nonalcoholic fatty liver]. | 2020 | Details |
| A06662 | 32790863 | Endocrinology | DPP-4 Inhibition with Anagliptin Reduces Lipotoxicity-Induced Insulin Resistance and Steatohepatitis in Male Mice. | 2020 | Details |
| A06673 | 32785100 | Diagnostics (Basel) | Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A06679 | 32782954 | JGH Open | Effect of telmisartan and vitamin E on liver histopathology with non-alcoholic steatohepatitis: A randomized, open-label, noninferiority trial. | 2020 | Details |
| A06680 | 32782883 | Cureus | An Observational Study of Reduction in Glycemic Parameters and Liver Stiffness by Saroglitazar 4 mg in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A06683 | 32781293 | Comp Biochem Physiol C Toxicol Pharmacol | Higher intestinal and circulatory lactate associated NOX2 activation leads to an ectopic fibrotic pathology following microcystin co-exposure in murine fatty liver disease. | 2020 | Details |
| A06684 | 32781086 | Gastroenterology | Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis. | 2020 | Details |
| A06692 | 32779242 | Hepatology | 17-Beta Hydroxysteroid Dehydrogenase 13 Deficiency Does Not Protect Mice From Obesogenic Diet Injury. | 2021 | Details |
| A06696 | 32777136 | FASEB J | Betulinic acid improves nonalcoholic fatty liver disease through YY1/FAS signaling pathway. | 2020 | Details |
| A06698 | 32776116 | Endocrinology | NAFLD and NASH in Postmenopausal Women: Implications for Diagnosis and Treatment. | 2020 | Details |
| A06699 | 32775976 | JHEP Rep | Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study. | 2020 | Details |
| A06702 | 32775350 | Visc Med | The Interplay between Alcoholic Liver Disease, Obesity, and the Metabolic Syndrome. | 2020 | Details |
| A06704 | 32775098 | Cureus | Vitamin E as an Adjuvant Treatment for Non-alcoholic Fatty Liver Disease in Adults: A Systematic Review of Randomized Controlled Trials. | 2020 | Details |
| A06705 | 32774848 | Ann Med Surg (Lond) | Spectrum of liver diseases in patients referred for Fibroscan: A single center experience in the Middle East. | 2020 | Details |
| A06706 | 32774765 | World J Gastrointest Surg | Role of micronutrients in staging of nonalcoholic fatty liver disease: A retrospective cross-sectional study. | 2020 | Details |
| A06719 | 32770818 | Liver Int | Steatosis as main determinant of portal hypertension through a restriction of hepatic sinusoidal area in a dietary rat nash model. | 2020 | Details |
| A06720 | 32770081 | Exp Mol Med | Immunological distinctions between nonalcoholic steatohepatitis and hepatocellular carcinoma. | 2020 | Details |
| A06725 | 32768394 | Ann Endocrinol (Paris) | Impact of aerobic training with and without whole-body vibration training on metabolic features and quality of life in non-alcoholic fatty liver disease patients. | 2020 | Details |
| A06726 | 32768187 | Biochem Biophys Res Commun | Blocking sphingosine 1-phosphate receptor 2 accelerates hepatocellular carcinoma progression in a mouse model of NASH. | 2020 | Details |
| A06735 | 32765720 | Exp Ther Med | Non-alcoholic fatty liver disease: A major challenge in type 2 diabetes mellitus (Review). | 2020 | Details |
| A06737 | 32765601 | Gastroenterol Res Pract | Mouse Models of Nonalcoholic Steatohepatitis: Head-to-Head Comparison of Dietary Models and Impact on Inflammation and Animal Welfare. | 2020 | Details |
| A06739 | 32765301 | Front Physiol | Lipophagy Impairment Is Associated With Disease Progression in NAFLD. | 2020 | Details |
| A06742 | 32763266 | J Hepatol | Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis. | 2020 | Details |
| A06744 | 32763196 | Lancet Gastroenterol Hepatol | A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. | 2020 | Details |
| A06746 | 32762728 | BMC Pharmacol Toxicol | Pharmacokinetic and metabolomic analyses of Mangiferin calcium salt in rat models of type 2 diabetes and non-alcoholic fatty liver disease. | 2020 | Details |
| A06752 | 32759852 | Int J Mol Sci | Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis. | 2020 | Details |
| A06755 | 32759166 | BMJ Open Diabetes Res Care | Association between non-alcoholic fatty liver disease-associated hepatic fibrosis and bone mineral density in postmenopausal women with type 2 diabetes or impaired glucose regulation. | 2020 | Details |
| A06757 | 32758151 | BMC Gastroenterol | Evaluation of NAFLD and fibrosis in obese patients - a comparison of histological and clinical scoring systems. | 2020 | Details |
| A06760 | 32757159 | Dig Dis Sci | External Validation of Four Point-of-Care Noninvasive Scores for Predicting Advanced Hepatic Fibrosis in a Predominantly Hispanic NAFLD Population. | 2020 | Details |
| A06761 | 32757050 | Eur Radiol | Diagnostic value of MRI-derived liver surface nodularity score for the non-invasive quantification of hepatic fibrosis in non-alcoholic fatty liver disease. | 2020 | Details |
| A06764 | 32756082 | Medicine (Baltimore) | Efficacy of vitamin D supplement in children with nonalcoholic fatty liver disease: A protocol for systematic review and meta-analysis. | 2020 | Details |
| A06766 | 32755310 | Am J Physiol Gastrointest Liver Physiol | The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. | 2020 | Details |
| A06768 | 32754942 | Magn Reson Med | Simultaneous proton density fat-fraction and R 2 ∗ imaging with water-specific T1 mapping (PROFIT1 ): application in liver. | 2020 | Details |
| A06775 | 32751794 | Int J Mol Sci | Cold Press Pomegranate Seed Oil Attenuates Dietary-Obesity Induced Hepatic Steatosis and Fibrosis through Antioxidant and Mitochondrial Pathways in Obese Mice. | 2020 | Details |
| A06782 | 32748075 | J Med Ultrason (2001) | Advances in ultrasound elastography for nonalcoholic fatty liver disease. | 2020 | Details |
| A06787 | 32745698 | Diabetes Res Clin Pract | Screening strategies for nonalcoholic fatty liver disease in type 2 diabetes: Insights from NHANES 2005-2016. | 2020 | Details |
| A06788 | 32745632 | Ann Hepatol | Increased serum selenium levels are associated with reduced risk of advanced liver fibrosis and all-cause mortality in NAFLD patients: National Health and Nutrition Examination Survey (NHANES) III. | 2020 | Details |
| A06790 | 32745314 | Liver Int | LncRNA NEAT1: Shedding light on mechanisms and opportunities in liver diseases. | 2020 | Details |
| A06793 | 32743224 | ACS Omega | Glycerol-3-phosphate Acyltransferase1 Is a Model-Agnostic Node in Nonalcoholic Fatty Liver Disease: Implications for Drug Development and Precision Medicine. | 2020 | Details |
| A06795 | 32742358 | Exp Ther Med | Pathophysiology of hepatic Na+/H+ exchange (Review). | 2020 | Details |
| A06798 | 32742124 | World J Gastroenterol | Management of nonalcoholic fatty liver disease in the Middle East. | 2020 | Details |
| A06807 | 32738385 | Alcohol | Moderate alcohol consumption is not associated with subclinical cardiovascular damage but with hepatic fibrosis in non-alcoholic fatty liver disease. | 2020 | Details |
| A06813 | 32737958 | Liver Int | Pulmonary function is associated with fibrosis severity in patients with biopsy-proven nonalcoholic fatty liver disease. | 2020 | Details |
| A06820 | 32734608 | J Pharm Pharmacol | HWL-088, a new and highly effective FFA1/PPARδ dual agonist, attenuates nonalcoholic steatohepatitis by regulating lipid metabolism, inflammation and fibrosis. | 2020 | Details |
| A06821 | 32734407 | Hepatol Int | Effect of COVID-19 on patients with compensated chronic liver diseases. | 2020 | Details |
| A06835 | 32730664 | Liver Int | Prognostic value of multiparametric magnetic resonance imaging, transient elastography and blood-based fibrosis markers in patients with chronic liver disease. | 2020 | Details |
| A06836 | 32730345 | PLoS One | Increased hepatic and circulating chemokine and osteopontin expression occurs early in human NAFLD development. | 2020 | Details |
| A06855 | 32720691 | Hum Mol Genet | Insights into genetic variants associated with NASH-fibrosis from metabolite profiling. | 2020 | Details |
| A06858 | 32720036 | Purinergic Signal | Design and in vivo activity of A3 adenosine receptor agonist prodrugs. | 2020 | Details |
| A06861 | 32719069 | J Pharmacol Exp Ther | The GPR40 Full Agonist SCO-267 Improves Liver Parameters in a Mouse Model of Nonalcoholic Fatty Liver Disease without Affecting Glucose or Body Weight. | 2020 | Details |
| A06865 | 32717951 | Cells | MicroRNA-221: A Fine Tuner and Potential Biomarker of Chronic Liver Injury. | 2020 | Details |
| A06867 | 32717363 | Ann Hepatol | Dietary consumption and serum pattern of bioactive fatty acids in NAFLD patients. | 2020 | Details |
| A06868 | 32717288 | J Hepatol | Targeting NFATc4 attenuates non-alcoholic steatohepatitis in mice. | 2020 | Details |
| A06870 | 32717123 | Aliment Pharmacol Ther | Improvement in histological endpoints of MAFLD following a 12-week aerobic exercise intervention. | 2020 | Details |
| A06871 | 32715793 | Expert Rev Gastroenterol Hepatol | Noninvasive diagnostic tools for pediatric NAFLD: where are we now? | 2020 | Details |
| A06878 | 32712221 | Metabolism | The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease. | 2020 | Details |
| A06879 | 32712103 | Gastroenterology | Progression of Fatty Liver Disease in Children Receiving Standard of Care Lifestyle Advice. | 2020 | Details |
| A06881 | 32711755 | J Pediatr | Muscle Mass Is Linked to Liver Disease Severity in Pediatric Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A06882 | 32711187 | Transl Res | The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet. | 2020 | Details |
| A06887 | 32709942 | Sci Rep | Prevalence and staging of non-alcoholic fatty liver disease among patients with heart failure with preserved ejection fraction. | 2020 | Details |
| A06900 | 32705195 | Mol Med Rep | Trimetazidine improves hepatic lipogenesis and steatosis in non‑alcoholic fatty liver disease via AMPK‑ChREBP pathway. | 2020 | Details |
| A06901 | 32704576 | Endocrinol Diabetes Metab | Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review. | 2020 | Details |
| A06903 | 32702591 | Phytomedicine | The water extract of Sophorae tonkinensis Radix et Rhizoma alleviates non-alcoholic fatty liver disease and its mechanism. | 2020 | Details |
| A06904 | 32702499 | Ann Hepatol | STAT3: A key regulator in liver fibrosis. | 2020 | Details |
| A06908 | 32701508 | JCI Insight | Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. | 2020 | Details |
| A06910 | 32700500 | Minerva Gastroenterol Dietol | Noninvasive diagnosis of fibrosis in non-alcoholic fatty liver disease: diagnostic accuracy of different scores. | 2020 | Details |
| A06911 | 32700499 | Minerva Gastroenterol Dietol | Fibromax and inflamatory markers cannot replace liver biopsy in the evaluation of non-alcoholic fatty liver disease. | 2020 | Details |
| A06913 | 32699233 | Sci Rep | MCD diet-induced steatohepatitis generates a diurnal rhythm of associated biomarkers and worsens liver injury in Klf10 deficient mice. | 2020 | Details |
| A06919 | 32698042 | Cell Mol Gastroenterol Hepatol | Impaired Hepatic Vitamin A Metabolism in NAFLD Mice Leading to Vitamin A Accumulation in Hepatocytes. | 2020 | Details |
| A06921 | 32697871 | Aliment Pharmacol Ther | Association between steatohepatitis biomarkers and hepatocellular carcinoma after hepatitis C elimination. | 2020 | Details |
| A06925 | 32696080 | Clin Res Cardiol | NAFLD and cardiovascular diseases: a clinical review. | 2020 | Details |
| A06933 | 32694734 | Nat Metab | Bone morphogenetic protein 8B promotes the progression of non-alcoholic steatohepatitis. | 2020 | Details |
| A06936 | 32694178 | Gut | Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. | 2020 | Details |
| A06951 | 32688339 | Endocr Connect | FGF21 regulates hepatic metabolic pathways to improve steatosis and inflammation. | 2020 | Details |
| A06958 | 32686578 | Expert Opin Emerg Drugs | Emerging drugs for the treatment of non-alcoholic steatohepatitis: a focused review of farnesoid X receptor agonists. | 2020 | Details |
| A06961 | 32685936 | Explor Med | Nonalcoholic fatty liver disease and portal hypertension. | 2020 | Details |
| A06964 | 32684985 | Diabetol Metab Syndr | NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. | 2020 | Details |
| A06965 | 32684739 | World J Gastroenterol | Medications in type-2 diabetics and their association with liver fibrosis. | 2020 | Details |
| A06967 | 32684060 | Scand J Gastroenterol | Biomarkers of liver fibrosis: prospective comparison of multimodal magnetic resonance, serum algorithms and transient elastography. | 2020 | Details |
| A06968 | 32683952 | Am J Physiol Gastrointest Liver Physiol | Knockout of sulfatase 2 is associated with decreased steatohepatitis and fibrosis in a mouse model of nonalcoholic fatty liver disease. | 2020 | Details |
| A06972 | 32682086 | Ann Hepatol | Hepatic transcriptome signature correlated with HOMA-IR explains early nonalcoholic fatty liver disease pathogenesis. | 2020 | Details |